Drenberg, Christina D <br/><br/>
A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML.  [electronic resource] 

 -  Nature communications  05 2019 
 - 2189 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2041-1723 
<br/><br/><label>Standard No.: </label>10.1038/s41467-019-09917-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Bone Marrow--pathology<br/>Bone Marrow Transplantation<br/>Cell Line, Tumor<br/>Child<br/>Child, Preschool<br/>Cytarabine--pharmacology<br/>Deoxycytidine--analogs & derivatives<br/>Disease-Free Survival<br/>Female<br/>High-Throughput Screening Assays--methods<br/>Humans<br/>Infant<br/>Janus Kinase Inhibitors--pharmacology<br/>Leukemia, Experimental--drug therapy<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Male<br/>Mice<br/>Mice, Inbred C57BL<br/>Mice, Transgenic<br/>Taxoids--pharmacology<br/>Whole-Body Irradiation--adverse effects<br/>Xenograft Model Antitumor Assays<br/>Young Adult<br/>Gemcitabine